Revefenacin
- Generic Name
- Revefenacin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C35H43N5O4
- CAS Number
- 864750-70-9
- Unique Ingredient Identifier
- G2AE2VE07O
- Background
Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LAMA group falls into a parent category known ...
- Indication
Revefenacin is indicated as an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
COPD is a growing disease being the third leading cause of death in the US. This disease is characterized by not fully reversible airflow limitation.
- Associated Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- -
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
- Conditions
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 404
- Registration Number
- NCT05165485
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site site 2, Clearwater, Florida, United States
🇺🇸Theravance Biopharma Investigational Site, Cudahy, Wisconsin, United States
🇺🇸Theravance Biopharma Investigational Site #2, Spartanburg, South Carolina, United States
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03573817
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Spartanburg, South Carolina, United States
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT03095456
- Locations
- 🇺🇸
Clinical Research of Rock Hill, Rock Hill, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.